Circulating Tumor DNA in Gastric Adenocarcinoma: Future Clinical Applications and Perspectives.
MRD
circulating tumor DNA
ctDNA
gastric cancer
liquid biopsy
minimal residual disease
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
29 May 2023
29 May 2023
Historique:
received:
30
04
2023
revised:
25
05
2023
accepted:
27
05
2023
medline:
12
6
2023
pubmed:
10
6
2023
entrez:
10
6
2023
Statut:
epublish
Résumé
Gastric cancer (GC) is still one of the most aggressive cancers with a few targetable alterations and a dismal prognosis. A liquid biopsy allows for identifying and analyzing the DNA released from tumor cells into the bloodstream. Compared to tissue-based biopsy, liquid biopsy is less invasive, requires fewer samples, and can be repeated over time in order to longitudinally monitor tumor burden and molecular changes. Circulating tumor DNA (ctDNA) has been recognized to have a prognostic role in all the disease stages of GC. The aim of this article is to review the current and future applications of ctDNA in gastric adenocarcinoma, in particular, with respect to early diagnosis, the detection of minimal residual disease (MRD) following curative surgery, and in the advanced disease setting for treatment decision choice and therapeutic monitoring. Although liquid biopsies have shown potentiality, pre-analytical and analytical steps must be standardized and validated to ensure the reproducibility and standardization of the procedures and data analysis methods. Further research is needed to allow the use of liquid biopsy in everyday clinical practice.
Identifiants
pubmed: 37298371
pii: ijms24119421
doi: 10.3390/ijms24119421
pmc: PMC10254023
pii:
doi:
Substances chimiques
Circulating Tumor DNA
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Ann Oncol. 2021 Sep;32(9):1167-1177
pubmed: 34176681
Mol Cancer. 2023 Jan 11;22(1):7
pubmed: 36627698
Nat Med. 2018 Sep;24(9):1449-1458
pubmed: 30013197
Lancet. 2023 May 20;401(10389):1655-1668
pubmed: 37068504
Ann Surg Oncol. 2019 Oct;26(11):3745-3755
pubmed: 31087180
Nat Rev Gastroenterol Hepatol. 2023 Mar;20(3):155-170
pubmed: 36344677
Anticancer Res. 2007 Jul-Aug;27(4C):2747-51
pubmed: 17695442
Clin Cancer Res. 2008 Oct 1;14(19):6264-9
pubmed: 18829507
Crit Rev Oncol Hematol. 2020 Jul;151:102978
pubmed: 32428812
Clin Cancer Res. 2018 Nov 15;24(22):5724-5734
pubmed: 29844130
PLoS One. 2012;7(12):e52465
pubmed: 23285052
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Oncol Lett. 2012 Apr 1;3(4):921-926
pubmed: 22741019
Diagnostics (Basel). 2020 Apr 13;10(4):
pubmed: 32294884
Cancer. 1983 Jun 1;51(11):2116-20
pubmed: 6188527
Clin Chem. 2022 Feb 1;68(2):354-364
pubmed: 34791072
Int J Mol Sci. 2021 Jul 06;22(14):
pubmed: 34298864
Oncotarget. 2017 Jan 10;8(2):3009-3017
pubmed: 27936467
Clin Cancer Res. 2019 Dec 1;25(23):7098-7112
pubmed: 31427281
BMC Gastroenterol. 2020 Nov 16;20(1):382
pubmed: 33198632
J Transl Med. 2023 Feb 11;21(1):118
pubmed: 36774504
Clin Cancer Res. 2021 Nov 15;27(22):6135-6144
pubmed: 34465601
Nat Commun. 2020 Jan 27;11(1):525
pubmed: 31988276
Anticancer Res. 2004 Jul-Aug;24(4):2477-81
pubmed: 15330201
Ann Oncol. 2022 Aug;33(8):750-768
pubmed: 35809752
World J Gastroenterol. 2008 Apr 7;14(13):2055-60
pubmed: 18395906
Cells. 2023 Mar 18;12(6):
pubmed: 36980276
Lab Invest. 2004 Apr;84(4):479-84
pubmed: 14968123
J Clin Oncol. 2019 Dec 10;37(35):3392-3400
pubmed: 31513484
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cell Death Dis. 2019 Sep 20;10(10):697
pubmed: 31541076
Int J Cancer. 2021 Apr 5;:
pubmed: 33818764
Cancer Metastasis Rev. 2020 Dec;39(4):1179-1203
pubmed: 32894370
World J Gastroenterol. 2018 Jun 7;24(21):2236-2246
pubmed: 29881233
J Clin Med. 2021 May 13;10(10):
pubmed: 34068319
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Mol Cancer. 2021 Jul 30;20(1):99
pubmed: 34330299
Gastric Cancer. 2017 Jan;20(1):126-135
pubmed: 26874951
Gut. 2012 May;61(5):673-84
pubmed: 22315472
Exp Mol Med. 2019 Aug 8;51(8):1-10
pubmed: 31395853
Nat Commun. 2017 Apr 10;8:15016
pubmed: 28393839
Mol Cancer. 2020 Oct 30;19(1):154
pubmed: 33126883
J Immunother. 2020 May;43(4):139-144
pubmed: 32134806
Am J Cancer Res. 2017 Nov 01;7(11):2199-2208
pubmed: 29218244
Oncotarget. 2016 Aug 5;8(33):54037-54045
pubmed: 28903321
J Hematol Oncol. 2022 Sep 12;15(1):131
pubmed: 36096847
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Oncotarget. 2016 Jul 26;7(30):48832-48841
pubmed: 27223063
Cancer Discov. 2019 Oct;9(10):1388-1405
pubmed: 31315834
Front Med (Lausanne). 2021 Sep 28;8:749250
pubmed: 34651002
Cancer Epidemiol Biomarkers Prev. 2020 May;29(5):895-902
pubmed: 32229577
Ann Surg Treat Res. 2014 Mar;86(3):136-42
pubmed: 24761422
Cancers (Basel). 2023 Mar 03;15(5):
pubmed: 36900369
JAMA Oncol. 2021 Jun 01;7(6):895-902
pubmed: 33792646
Cancer Sci. 2003 May;94(5):418-20
pubmed: 12824886
Lancet Oncol. 2022 Nov;23(11):1430-1440
pubmed: 36244398
Cancer Cell. 2015 Nov 9;28(5):666-676
pubmed: 26525104
Lancet. 2020 Aug 29;396(10251):635-648
pubmed: 32861308
Life (Basel). 2021 Aug 28;11(9):
pubmed: 34575039
Clin Adv Hematol Oncol. 2022 Jul;20(7):444-455
pubmed: 35802877
Cureus. 2021 Nov 1;13(11):e19189
pubmed: 34873529
Ann Oncol. 2022 Oct;33(10):1005-1020
pubmed: 35914639
Gut. 2019 Jul;68(7):1152-1161
pubmed: 30269082
Oncol Ther. 2021 Jun;9(1):89-110
pubmed: 33689160
N Biotechnol. 2020 Mar 25;55:19-29
pubmed: 31580920
Int J Cancer. 2020 Jan 1;146(1):272-280
pubmed: 31162842
Cell Death Dis. 2022 Oct 27;13(10):903
pubmed: 36302755
Cell Rep. 2020 May 5;31(5):107550
pubmed: 32375028
Front Oncol. 2022 Sep 15;12:969866
pubmed: 36185234
Crit Rev Oncol Hematol. 2020 Dec;156:103112
pubmed: 33035734
Gastric Cancer. 2014 Jan;17(1):26-33
pubmed: 23572188
Cancers (Basel). 2019 May 27;11(5):
pubmed: 31137920
Nat Commun. 2020 Feb 5;11(1):730
pubmed: 32024845
Cancer Med. 2021 Mar;10(6):2003-2012
pubmed: 33641249
Cell Death Dis. 2020 May 11;11(5):346
pubmed: 32393783
ESMO Open. 2022 Aug;7(4):100547
pubmed: 35849878
Eur J Cancer. 2018 Jan;88:92-100
pubmed: 29207318
Tumour Biol. 2017 Apr;39(4):1010428317695012
pubmed: 28381156
N Engl J Med. 2020 Jun 18;382(25):2419-2430
pubmed: 32469182
Lancet. 2021 Jul 3;398(10294):27-40
pubmed: 34102137
Mol Cancer. 2019 Mar 15;18(1):41
pubmed: 30876419
PLoS One. 2013 Jun 27;8(6):e67195
pubmed: 23826230
BMC Cancer. 2022 Sep 27;22(1):1020
pubmed: 36167530